August 19, 2011
VerathonÂ® Introduces the Heartscape(TM) 3D ECG System with 80-Lead Vest in Europe; Technology Provides More Complete Data to Help Diagnose Acute Myocardial Infarction (MI)
BOTHELL, Wash., Aug. 19, 2011 /PRNewswire/ -- Verathon Inc. is pleased to introduce in Europe the Heartscape(TM) 3D ECG System with 80-lead vest, designed to give Emergency Department (ED) physicians, Interventional Cardiologists, and ED nurses a more complete diagnostic picture by providing a 360 degree electrocardiographic view of the heart.http://photos.prnewswire.com/prnh/20061011/SFW044LOGO)
The Heartscape 3D ECG System, successor to the PRIMEÃ® ECG technology, uses the same clinically supported diagnostic algorithm to help physicians identify indications of possible Myocardial Infarction (MI) - including MIs without ST-segment elevation on traditional 12-lead ECGs, and in patients with Left Bundle Branch Block (LBBB). Studies demonstrate greater sensitivity and comparable specificity in detecting acute MIs compared to 12-lead ECGs.(1-3) All told, numerous studies - collectively involving thousands of patients - have shown that the Heartscape system's 80-lead technology can improve early diagnosis and help detect acute MIs missed by traditional 12-lead ECGs. To review clinical studies, visit verathon.com/heartscapeEU.
The device's unique design features a rapid-application 2-part Vest containing 80 leads, and an intuitive touchscreen color monitor that displays the Heartscape 360 degree Exam. The Heartscape system facilitates rapid data input and exam results to help accelerate triage for cardiac patients, making it ideal for emergency settings.
"Emergency physicians and Interventional Cardiologists told us that more definitive ECG information could help them identify high-risk cardiac patients more quickly, when seconds count," stated Gerald McMorrow, founder and CEO of Verathon. "By offering a 360 degree view of the electrical activity of the heart, Heartscape is designed to help healthcare providers assess the patients' status faster and accelerate their treatment. We believe that with more accurate diagnosis, better outcomes and lower costs are the result."
According to the statistical office of the European Union, the average total number of deaths caused by ischemic cardiopathy in 27 selected European countries was over 693,000 from 2007 - 2009.(4) In France alone, where this year's European Society of Cardiology is convening, it is estimated that every year approximately 100,000 patients are affected by myocardial infarction.(5)
Heartscape applications include standard ECGs and non-diagnostic 12-lead ECGs, such as Anterior MIs, Posterior MIs, Inferior MIs, and more Lateral MIs (outside of the standard 12-lead view). The Heartscape system can also assist with confounding factors such as Bundle Branch Blocks (eg, LBBBs), Early Repolarization, or Left Ventricular Hypertrophy (LVH).
The Heartscape 3D ECG System debuts at the European Society of Cardiology in Paris, France on August 27, 2011 (Booth A334, Hall 6). A U.S. introduction is anticipated in 2012. For more information, visit verathon.com/heartscapeEU.
About the Heartscape 2-Part Vest System
The proprietary 80-lead Vest System consists of 2 parts and provides 58 anterior leads, 12 lateral leads, and 10 posterior leads. Available in 4 sizes (small, medium, large, and extra large), the vest is designed to quickly and comfortably fit a wide range of adult male and female patients.
About the Heartscape 360 degree Exam
The Heartscape system provides three options for exam results: an anatomical tracing from 80 leads, a 12-lead tracing, and the new Heartscape 360 degree Exam which indicates ST Elevation (STEMI), ST Depression, NSTEMI, and other heart abnormalities in an easy-to-read, rotating 3D color-graphic diagnostic algorithm.
Designed for ease of use, the Heartscape touchscreen monitor offers a short video tutorial on how to utilize the system. A wireless color printer is also included for printing hard copies of exam results. The Heartscape 3D ECG System is battery powered and comes with a 1-year warranty.
About Verathon Inc.
VerathonÃ® designs and manufactures reliable, state-of-the-art medical devices and services that offer a meaningful improvement in patient care to the healthcare community. The company's noninvasive BladderScanÃ® instrument is a standard of care for portable bladder volume measurement. The brand is found in over 60 countries in Urology and Primary Care practices, as well as Acute and Extended Care facilities. With the January 2006 acquisition of Saturn Biomedical Systems in Vancouver, Canada, Verathon entered Anesthesiology, Critical Care and Emergency markets with the GlideScopeÃ® video laryngoscope brand. Verathon is headquartered in Bothell, Washington and operates as a subsidiary of Roper Industries. For more information, please visit www.verathon.com.
About Roper Industries
Roper Industries is a market-driven, diversified growth company and is a constituent of the S&P 500, Fortune 1000, and the Russell 1000 indices. Roper provides engineered products and solutions for global niche markets, including water, energy, transportation, medical, education, and SaaS-based information networks. Additional information about Roper Industries is available on the Company's website at www.roperind.com.
Verathon Media Contacts: Todd Berard, New Product Manager, Verathon Medical, 425.867.1348 (Ext. 5686). Alternate Contact: Jane Mueller, VP of Marketing, 425.867.1348 (Ext. 5600).
References: 1. Owens et al. Prehospital 80-lead mapping: Does it add significantly to the diagnosis of acute coronary syndrome? J Electrocard. 2004/37(suppl): 223-232. 2. McClelland et al. Comparison of the 80-lead body surface map to physician and to 12-lead electrocardiogram in detection of acute myocardial infarction. Am J Cardiol. 2003/92: 252-257. 3. Ornato et al. Body surface mapping vs 12-lead electrocardiography to detect ST-elevation mycocardial infarction. Am J Emerg Med. 2009/27: 779-784. 4. Ischaemic heart diseases (ICD 120-125). European Commission Eurostat Web site. Available at: http://appsso.eurostat.ec.europa.eu/nui/show.do. Accessed August 8, 2011. 5. Together, let's improve myocardial infarction management: A progress report in 2009. Haute Autorite de Sante Web site. Available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-11/idm_etape_3_v5_en_vf.pdf. Accessed August 5, 2011.
BladderScan, GlideScope, Heartscape, Verathon, and the Verathon Torch symbol are registered trademarks of Verathon Inc.
Ã© 2011 Verathon Inc.
SOURCE Verathon Inc.